#United States #San Diego #Robbins LLP #REGENXBIO #RGNX

REGENXBIO, Inc. Class Action Reminder

In a significant development for REGENXBIO, Inc. (NASDAQ: RGNX) shareholders, Robbins LLP has issued a reminder regarding a class action lawsuit that could impact many investors. The firm is encouraging all shareholders who acquired REGENXBIO securities between February 9, 2022, and January 27, 2026, to be aware of their rights and the ongoing litigation.

Background of the Class Action

REGENXBIO, based in San Diego, is a clinical-stage biotechnology firm specializing in gene therapies designed to treat genetic defects in patients. The relevant class action arises from allegations that the company misled investors about its lead drug candidate, RGX-111. According to the allegations, the company had consistently promoted RGX-111, touting positive results from its clinical trials, and had even received Fast Track designation from the FDA back in 2018. However, the complaint suggests that behind the scenes, the company was fully aware of serious safety concerns relating to RGX-111, particularly the potential risk of CNS tumors.

Key Allegations

The complaint reveals that on January 28, 2026, REGENXBIO disclosed that the FDA had placed a clinical hold on RGX-111 due to preliminary analysis indicating a case of a serious intraventricular CNS tumor in a participant. This news had a significant adverse effect on REGENXBIO's stock, causing a sharp decline from $13.41 to $11.01 in one day—a 17.8% drop.

This sudden decline raised alarms among investors, leading to the subsequent class action aimed at holding the company accountable for the alleged misleading statements about the safety and viability of their drug candidate. Robbins LLP is now inviting shareholders to come forward if they wish to participate as lead plaintiffs in the class action.

What Shareholders Should Do

Interested shareholders need to act quickly, as any formal submissions to serve as lead plaintiffs must be filed by April 14, 2026. Importantly, potential lead plaintiffs do not need to actively participate in the case to be eligible for any recovery if the court rules in favor of the shareholders.

Robbins LLP will handle representation on a contingency basis, which means no upfront fees for shareholders—instead, they only pay if they successfully recover funds through the litigation.

Why This Matters

The outcome of this class action could be pivotal not just for REGENXBIO investors but for the biotech industry at large, as it underscores the importance of transparent communication between companies and their shareholders. This class action serves as a reminder of the responsibilities that public companies have towards their investors, particularly in addressing safety and efficacy concerns related to their products.

About Robbins LLP

Founded in 2002, Robbins LLP is a leading firm in the field of shareholder rights litigation. The attorneys possess extensive experience in helping shareholders recover losses and in improving corporate governance. Their commitment to holding corporate executives accountable has made them a recognized leader in this field.

For investors seeking updates on the court proceedings or wishing to sign up for alerts about settlements, Robbins LLP offers a ‘Stock Watch’ service designed to keep shareholders informed.

In summary, REGENXBIO investors are encouraged to reach out to Robbins LLP to understand their rights, follow the developments of the class action, and consider participating in the litigation process. This case serves as an essential reminder of the importance of investor vigilance and corporate accountability in the rapidly evolving world of biotechnology.